---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-095931"
form_type: "8-K"
ticker: "FBIO"
cik: "0001429260"
company_name: "Fortress Biotech, Inc."
filed_at: "2026-08-13T20:15:21+00:00"
generated_at: "2026-08-13T20:17:56.405334+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Fortress Biotech Q2 2026 revenue up 14% to $18.7M; net loss $2.5M vs prior-year income

## Summary
- Q2 2026 net revenue $18.7M (up 14% YoY from $16.4M); net loss attributable to common stockholders $(2.5)M ($0.08/share) vs net income $13.4M ($0.50/share) in Q2 2025.
- Cash and equivalents $196.6M at June 30, 2026, up from $79.4M at Dec 31, 2025, boosted by $205M PRV sale from ZYCUBO.
- Crystalys closed $130M Series B financing for dotinurad; Urica holds equity and 3% royalty on future net sales.
- Journey Medical expanded Emrosi payer access to over 150M commercial lives (~85% of US commercial lives); Q2 net product revenue $17.8M vs $15.0M YoY.
- AstraZeneca reported anselamimab subgroup analysis: 62% survival improvement and 71% reduction in cardiovascular hospitalizations in kappa AL amyloidosis; regulatory submission planned.

## SEC filing metadata
- accession: 0001104659-26-095931
- form_type: 8-K
- ticker: FBIO
- cik: 0001429260
- company_name: Fortress Biotech, Inc.
- filed_at: 2026-08-13T20:15:21+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1429260/000110465926095931/0001104659-26-095931-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1429260/000110465926095931/fbio-20260813x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-095931
- JSON: https://secwatch.observer/filing/0001104659-26-095931.json
- Plain text: https://secwatch.observer/filing/0001104659-26-095931.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.